TREMFYA
Total Payments
$91.7M
Transactions
464,852
Doctors
37,955
Companies
7
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $37.1M | 194,214 | 30,841 |
| 2023 | $29.4M | 118,376 | 16,781 |
| 2022 | $18.1M | 83,704 | 12,995 |
| 2021 | $4.2M | 52,290 | 10,063 |
| 2020 | $2.9M | 16,238 | 4,603 |
| 2019 | $28,852 | 30 | 10 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $44.6M | 10,895 | 48.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24.7M | 9,612 | 26.9% |
| Food and Beverage | $9.0M | 406,354 | 9.8% |
| Consulting Fee | $7.3M | 2,721 | 8.0% |
| Travel and Lodging | $3.8M | 9,573 | 4.1% |
| Education | $2.2M | 25,657 | 2.4% |
| Space rental or facility fees (teaching hospital only) | $125,300 | 40 | 0.1% |
Payments by Type
General
$47.1M
453,957 transactions
Research
$44.6M
10,895 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | Janssen Research & Development, LLC | $7.1M | 1 |
| CNTO1959PSO3018 | Janssen Research & Development, LLC | $7.0M | 0 |
| CNTO1959PSO3017 | Janssen Research & Development, LLC | $6.2M | 0 |
| Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | Janssen Research & Development, LLC | $3.8M | 0 |
| CNTO1959CRD3004 | Janssen Research & Development, LLC | $3.0M | 0 |
| A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | Janssen Research & Development, LLC | $2.9M | 0 |
| A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | Janssen Research & Development, LLC | $2.7M | 0 |
| A Phase 2a Multi Center Randomized Double blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab and Golimumab Combination Therapy in Participants with Active Psoriatic Arthritis | Janssen Research & Development, LLC | $1.6M | 0 |
| CNTO1959PSA3004 | Janssen Research & Development, LLC | $1.5M | 0 |
| CNTO1959PSA3006_Ogdie_Guselkumab vs Golimeumab in PsA TNF Inadequate Responder Patients: a pragmatic trial (EVOLUTION) | Janssen Research & Development, LLC | $1.4M | 0 |
| PSOLAR | Janssen Research & Development, LLC | $1.3M | 2 |
| A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | Janssen Research & Development, LLC | $1.2M | 0 |
| Scher_Preventing Arthritis in a Multi-Center Psoriasis At-Risk Cohort (Multi-center PAMPA Study) | Janssen Research & Development, LLC | $1.1M | 0 |
| CNTO1959PSA3006_Ogdie_Guselkumab vs Golimeumab in PsA TNF Inadequate Responder Patients: a pragmatic trial | Janssen Research & Development, LLC | $482,639 | 0 |
| Immunogenetic Profiling Of Guselkumab For The Treatment Of Plaque And Guttate Psoriasis | Janssen Research & Development, LLC | $353,049 | 0 |
| An Open label Randomized Parallel group Study to Assess the Pharmacokinetic Comparability of Subcutaneously Administered Guselkumab Delivered by 3 Different Devices in Healthy Participants | Janssen Research & Development, LLC | $333,753 | 0 |
| A Multi Center open registry of patients with psoriasis who are candidates for systematic therapy including biologics | Janssen Research & Development, LLC | $312,023 | 2 |
| An open label pilot trial of guselkumab in the treatment of adults with pityriasis rubra pilaris PRP | Janssen Research & Development, LLC | $280,454 | 0 |
| A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Guselkumab in Subjects with Active Lupus Nephritis | Janssen Research & Development, LLC | $258,022 | 0 |
| A Study to Evaluate the Efficacy Safety and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants | Janssen Research & Development, LLC | $252,342 | 0 |
Top Doctors Receiving Payments for TREMFYA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $44.8M | 11,030 |
| , MD | Dermatology | Winston Salem, NC | $551,293 | 332 |
| , M.D | Dermatology | Sioux Falls, SD | $457,837 | 379 |
| , M.D | Dermatology | Exton, PA | $392,031 | 328 |
| , M.D | Dermatology | Lackland Afb, TX | $386,752 | 398 |
| , MD | Student in an Organized Health Care Education/Training Program | New York, NY | $366,319 | 322 |
| , M.D | Dermatology | Cornelius, NC | $347,789 | 369 |
| Lori Cox | Rheumatology | New Brunswick, NJ | $339,085 | 13 |
| , M.D | Dermatology | Northbrook, IL | $336,355 | 283 |
| , MD | Dermatology | Pittsburgh, PA | $307,883 | 277 |
| , M.D., M.B.A | Dermatology | Farmington, CT | $304,418 | 322 |
| , MD | Dermatology | Macon, GA | $298,593 | 292 |
| , MD | Dermatology | Plainfield, IN | $287,331 | 242 |
| , M.D | Dermatology | Hickory, NC | $285,731 | 207 |
| , D.O | Family Medicine | Stuart, FL | $278,492 | 250 |
| Mona Shahriari | Dermatology | Cromwell, CT | $275,835 | 217 |
| , M.D | MOHS-Micrographic Surgery | Bakersfield, CA | $275,819 | 286 |
| , PA | Physician Assistant | Maitland, FL | $275,182 | 642 |
| , MD | Dermatology | Bellevue, WA | $268,149 | 382 |
| , M.D | Dermatology | Santa Ana, CA | $261,022 | 301 |
| , M.D., PHD | Dermatology | Santa Monica, CA | $249,360 | 399 |
| , M.D | Pediatric Dermatology | Centennial, CO | $230,237 | 183 |
| , MD | Procedural Dermatology | Phoenix, AZ | $225,840 | 310 |
| , PA-C | Surgical | Brandon, FL | $223,833 | 448 |
| , PA | Medical | Woodstock, GA | $217,569 | 309 |
Ad
Manufacturing Companies
- Janssen Research & Development, LLC $45.2M
- Janssen Biotech, Inc. $33.9M
- Janssen Scientific Affairs, LLC $12.1M
- Janssen Global Services, LLC $408,648
- Janssen Pharmaceuticals, Inc $88,504
- Johnson & Johnson Health Care Systems Inc. $14,415
- Johnson & Johnson Vision Care, Inc. $54.92
Product Information
- Type Drug
- Total Payments $91.7M
- Total Doctors 37,955
- Transactions 464,852
About TREMFYA
TREMFYA is a drug associated with $91.7M in payments to 37,955 healthcare providers, recorded across 464,852 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Research & Development, LLC.
Payment data is available from 2019 to 2024. In 2024, $37.1M was paid across 194,214 transactions to 30,841 doctors.
The most common payment nature for TREMFYA is "Unspecified" ($44.6M, 48.6% of total).
TREMFYA is associated with 20 research studies, including "A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease" ($7.1M).